Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 4, 2015, Pages 661-668

  Dalhoff, A ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; DNA HELICASE; DNA TOPOISOMERASE; QUINOLONE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AJELLOMYCES CAPSULATUS; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIPARASITIC ACTIVITY; ANTIVIRAL ACTIVITY; APICOMPLEXA; ASPERGILLUS FUMIGATUS; BABESIA; BACTERIAL INFECTION; BK VIRUS INFECTION; CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDIASIS; COCCIDIOIDES; CURVULARIA; DNA REPLICATION; DRUG EFFICACY; DRUG MECHANISM; ENCEPHALITOZOON INTESTINALIS; ENZYME INHIBITION; ESCHERICHIA COLI; EXOPHIALA SPINIFERA; HEPATITIS C; HUMAN; LEISHMANIA; MALARIA; MALARIA FALCIPARUM; MYCOSIS; NONHUMAN; PAECILOMYCES; PARASITOSIS; PHENOTYPE; PLASMODIUM; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA REPLICATION; SEVERE ACUTE RESPIRATORY SYNDROME; SIMIAN VIRUS 40; TOXOPLASMA; VIRUS INFECTION; VIRUS REPLICATION; VITTAFORMA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG REPOSITIONING; METABOLISM;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIPARASITIC AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DNA HELICASES; DNA TOPOISOMERASES, TYPE I; DRUG REPOSITIONING; FLUOROQUINOLONES; HUMANS;

EID: 84925061725     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2296-3     Document Type: Review

References (124)

1. Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP (1962) 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 5:1063–1065
2. Slater AF, Cerami A (1992) Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature 355:167–169
3. Slater AF (1993) Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther 57:203–235
4. Ginsburg H, Famin O, Zhang J, Krugliak M (1998) Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem Pharmacol 56:1305–1313
5. Savarino A, Gennero L, Sperber K, Boelaert JR (2001) The anti-HIV-1 activity of chloroquine. J Clin Virol 20:131–135
6. Savarino A, Gennero L, Chen HC, Serrano D, Malavasi F, Boelaert JR, Sperber K (2001) Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS 15:2221–2229
7. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 3:722–727
8. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A (2006) New insights into the antiviral effects of chloroquine. Lancet Infect Dis 6:67–69
9. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. doi:10.1186/1743-422X-2-69
10. Di Trani L, Savarino A, Campitelli L, Norelli S, Puzelli S, D’Ostilio D, Vignolo E, Donatelli I, Cassone A (2007) Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J 4:39. doi:10.1186/1743-422X-4-39
11. + T-lymphocytes. Retrovirology 4:6. doi:10.1186/1742-4690-4-6
12. Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P (2009) Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 53:3416–3421
13. Rolain JM, Colson P, Raoult D (2007) Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30:297–308
14. Harrison TS, Griffin GE, Levitz SM (2000) Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans. J Infect Dis 182:283–289
15. Khan MA, Jabeen R, Nasti TH, Mohammad O (2005) Enhanced anticryptococcal activity of chloroquine in phosphatidylserine-containing liposomes in a murine model. J Antimicrob Chemother 55:223–228
16. Doi S, Tanabe K, Watanabe M, Yoshimura M (1988) Chloroquine, a lysosomotropic agent, inhibits zygote formation in yeast. Arch Microbiol 151:20–25
17. Ciak J, Hahn FE (1966) Chloroquine: mode of action. Science 151:347–349
18. Acheampong YB (1988) Kinetics of bacteriostatic activity of chloroquine on Staphylococcus aureus. Indian J Pharm Sci 50:40–42
19. Smith KT, Dawes IW (1989) The preferential inhibition of Bacillus subtilis spore outgrowth by chloroquine. Arch Microbiol 152:251–257
20. Wolf R, Baroni A, Greco R, Donnarumma G, Ruocco E, Tufano MA, Ruocco V (2002) Quinine sulfate and bacterial invasion. Ann Clin Microbiol Antimicrob 1:5
21. Ramos-Avila A, Ventura-Gallegos JL, Zentella-Dehesa A, Machuca-Rodríguez C, Moreno-Altamirano MM, Narváez V, Legorreta-Herrera M (2007) Immunomodulatory role of chloroquine and pyrimethamine in Plasmodium yoelii 17XL infected mice. Scand J Immunol 65:54–62
22. Schultz KR, Gilman AL (1997) The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. Leuk Lymphoma 24:201–210
23. Cooper RG, Magwere T (2008) Chloroquine: novel uses & manifestations. Indian J Med Res 127:305–316
24. Yi AK, Peckham DW, Ashman RF, Krieg AM (1999) CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol 11:2015–2024
25. Thomé R, Moraes AS, Bombeiro AL, dos Santos Farias A, Francelin C, da Costa TA, Di Gangi R, Barbosa dos Santos LM, Rodrigues de Oliveira AL, Verinaud L (2013) Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis. PLoS One 8(6):e65913. doi:10.1371/journal.pone.0065913
26. Vezmar M, Georges E (2000) Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol 59:1245–1252
27. Zamora JM, Pearce HL, Beck WT (1988) Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33:454–462
28. Klohs WD, Steinkampf RW (1988) The effect of lysosomotropic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells. Mol Pharmacol 34:180–185
29. Lee CM, Tannock IF (2006) Inhibition of endosomal sequestration of basic anticancer drugs: Influence on cytotoxicity and tissue penetration. Br J Cancer 94:863–869
30. Zhao H, Cai Y, Santi S, Lafrenie R, Lee H (2005) Chloroquine-mediated radiosensitization is due to the destabilization of the lysosomal membrane and subsequent induction of cell death by necrosis. Radiat Res 164:250–257
31. Jensen PB, Sørensen BS, Sehested M, Grue P, Demant EJ, Hansen HH (1994) Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res 54:2959–2963
32. Langer SW, Schmidt G, Sørensen M, Sehested M, Jensen PB (1999) Inhibitors of topoisomerase II as pH-dependent modulators of etoposide-mediated cytotoxicity. Clin Cancer Res 5:2899–2907
33. Schneider YJ, Trouet A (1981) Effect of chloroquine and methylamine on endocytosis of fluorescein-labelled controlled IgG and of anti-(plasma membrane) IgG by cultured fibroblasts. Eur J Biochem 118:33–38
34. Pecivová J, Drábiková K, Nosál R (1994) Effect of chloroquine on mast cell membranes. Agents Actions 41(Suppl):C43–C44
35. Chesney RW, Budreau AM (1995) Chloroquine, a novel inhibitor of amino acid transport by rat renal brush border membrane vesicles. Amino Acids 8:141–158
36. Rodríguez-Menchaca AA, Navarro-Polanco RA, Ferrer-Villada T, Rupp J, Sachse FB, Tristani-Firouzi M, Sánchez-Chapula JA (2008) The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. Proc Natl Acad Sci U S A 105:1364–1368
37. Noujaim SF, Stuckey JA, Ponce-Balbuena D, Ferrer-Villada T, López-Izquierdo A, Pandit SV, Sánchez-Chapula JA, Jalife J (2011) Structural bases for the different anti-fibrillatory effects of chloroquine and quinidine. Cardiovasc Res 89:862–869
38. Betbeder D, Hutchison DW, Baltz T, Cros S (1988) Trypanocidal and antitumor activities of nalidixic and oxolinic acid derivatives. Med Sci Res 16:141–142
39. Furet YX, Pechère JC (1991) Newly documented antimicrobial activity of quinolones. Eur J Clin Microbiol Infect Dis 10:249–254
40. Segev S, Rubinstein E (1998) Future aspects. In: Kuhlmann J, Dalhoff A, Zeiler H-J (eds) Handbook of experimental pharmacology, vol. 127: quinolone antibacterials. Springer-Verlag, Berlin, Heidelberg, New York, pp 455–477
41. Eliopoulos GM, Eliopoulos CT (1993) Activity in vitro of the quinolones. In: Hooper DC, Wolfson JS (eds) Quinolone antimicrobial agents, 2nd edn. ASM Press, Washington, DC, pp 161–193
42. Shen LL (1993) Quinolone–DNA interaction. In: Hooper DC, Wolfson JS (eds) Quinolone antimicrobial agents, 2nd edn. ASM Press, Washington, DC, pp 77–95
43. Palù G, Valisena S, Peracchi M, Palumbo M (1988) Do quinolones bind to DNA? Biochem Pharmacol 37:1887–1888
44. Shen LL (1989) A reply: “Do quinolones bind to DNA?”—Yes. Biochem Pharmacol 38:2042–2044
45. Laponogov I, Sohi MK, Veselkov DA, Pan XS, Sawhney R, Thompson AW, McAuley KE, Fisher LM, Sanderson MR (2009) Structural insight into the quinolone–DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol 16:667–669
46. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD (2010) Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol 17:1152–1153
47. Hamilton-Miller JMT (1999) beta-lactams: variations on a chemical theme, with some surprising biological results. J Antimicrob Chemother 44:729–734
48. Dalhoff A (1987) Pleiotropic actions of aminoglycosides.In: Döring G, Holder IA, Botzenhart K (eds) Antibiotics and chemotherapy. Basic research and clinical aspects of Pseudomonas aeruginosa. Karger, Basel, pp 182–204
49. Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369–413
50. Corbett KD, Berger JM (2004) Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct 33:95–118
51. Pommier Y, Leo E, Zhang HL, Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17:421–433
52. Forterre P, Gadelle D (2009) Phylogenomics of DNA topoisomerases: their origin and putative roles in the emergence of modern organisms. Nucleic Acids Res 37:679–692. doi:10.1093/nar/gkp032
53. Chen SH, Chan NL, Hsieh TS (2013) New mechanistic and functional insights into DNA topoisomerases. Annu Rev Biochem 82:139–170
54. Takada A, Takase S, Tsutsumi M, Sawada M (1993) Effects of ofloxacin for type C hepatitis. Int Hepatol Commun 1:272–277
55. Kojima H, Kaita KDE, Hawkins K, Uhanova J, Minuk GY (2002) Use of fluoroquinolones in patients with chronic hepatitis C virus-induced liver failure. Antimicrob Agents Chemother 46:3280–3282
56. Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, Liang R, Lie AK, Kwong YL (2005) Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 40:528–537
57. Chandraker A, Ali S, Drachenberg CB, Wali R, Hirsch H, DeCaprio J, Ramos E (2004) Use of fluoroquinolones to treat BK infection in renal transplant recipients [Abstract]. Am J Transplant 4:587
58. Gabardi S, Waikar SS, Martin S, Roberts K, Chen J, Borgi L, Sheashaa H, Dyer C, Malek SK, Tullius SG, Vadivel N, Grafals M, Abdi R, Najafian N, Milford E, Chandraker A (2010) Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol 5:1298–1304
59. Arroyo D, Chandran S, Vagefi PA, Wojciechowski D (2014) Adjuvant ciprofloxacin for persistent BK polyomavirus infection in kidney transplant recipients. J Transplant 2014:107459. doi:10.1155/2014/107459
60. Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH (2011) Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antiviral Res 92:115–123
61. Randhawa PS (2005) Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin Infect Dis 41:1366–1367
62. Ali S, Chandraker A, DeCaprio J (2003) Inhibition of polyoma helicase activity by quinolones. J Am Soc Nephrol 14:43A
63. Ali SH, Chandraker A, DeCaprio J (2007) Inhibition of simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther 12:1–6
64. Khan IA, Siddiqui S, Rehmani S, Kazmi SU, Ali SH (2012) Fluoroquinolones inhibit HCV by targeting its helicase. Antivir Ther 17:467–476
65. Umbro I, Anzivino E, Tinti F, Zavatto A, Bellizzi A, Rodio DM, Mancini C, Pietropaolo V, Mitterhofer AP (2013) Possible antiviral effect of ciprofloxacin treatment on polyomavirus BK replication and analysis of non-coding control region sequences. Virol J 10:274
66. Humar A, Gill J, Johnston O, Fergusson D, House AA, Lebel L, Cockfield S, Kim SJ, Zaltzman J, Cantarovich M, Karpinski M, Ramsay T, Knoll GA (2013) Quinolone prophylaxis for the prevention of BK virus infection in kidney transplantation: study protocol for a randomized controlled trial. Trials 14:185
67. Patel SJ (2014) Ciprofloxacin for prevention of BK infection. ClinicalTrials.gov identifier: NCT01789203, last updated June 24, 2014, last visited October 8, 2014
68. Ikeda S, Yazawa M, Nishimura C (1987) Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative. Antiviral Res 8:103–113
69. Kamau E, Grove A (2004) Fluoroquinolone-dependent DNA supercoiling by vaccinia topoisomerase I. J Mol Biol 342:479–487
70. Pessina A, Mineo E, Gribaldo L, Neri MG (1992) Lack of in vitro antiviral activity of fluoroquinolones against herpes simplex virus type 2. Arch Virol 122:263–269
71. Gurtler L, Eberle J, Deinhardt F (1989) Inhibition of HIV reverse transcriptase by 4-quinolones. In: Proceedings of the 5th International Conference on AIDS, Montreal, Canada, June 1989, abstract no. C624
72. Grohe K, Dummer W, Rossen K, Paessens A (1991) Quinolone carboxylic acid derivatives, process for their preparation and their use. Patent number 0422485 A2
73. Grohe K, Dummer W, Rossen K, Paessens A (1993) Quinolone carboxylic acid derivatives and their use as antiviral agents. Patent number US5217972 A
74. Yamaya M, Nishimura H, Hatachi Y, Yasuda H, Deng X, Sasaki T, Mizuta K, Kubo H, Nagatomi R (2012) Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Antimicrob Agents Chemother 56:4052–4061
75. Ozdek SC, Miller D, Flynn PM, Flynn HW (2006) In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections. Ocul Immunol Inflamm 14:347–351
76. Sultana N, Naz A, Khan B, Arayne MS, Mesiak MA (2010) Synthesis, characterization, antibacterial, antifungal, and immunomodulating activities of gatifloxacin derivatives. Med Chem Res 19:1210–1221
77. Stergiopoulou T, Meletiadis J, Sein T, Papaioannidou P, Tsiouris I, Roilides E, Walsh TJ (2009) Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. J Antimicrob Chemother 63:343–348
78. Stergiopoulou T, Meletiadis J, Sein T, Papaioannidou P, Tsiouris I, Roilides E, Walsh TJ (2008) Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus. Antimicrob Agents Chemother 52:2196–2204
79. Stergiopoulou T, Meletiadis J, Sein T, Papaioannidou P, Walsh TJ, Roilides E (2011) Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus. Antimicrob Agents Chemother 55:5923–5929
80. Sugar AM, Liu XP, Chen RJ (1997) Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs. Antimicrob Agents Chemother 41:2518–2521
81. Petrou MA, Rogers TR (1988) In-vitro activity of antifungal agents in combination with four quinolones. Drugs Exp Clin Res 14:9–18
82. Deren YT, Özdek S, Kalkanci A, Akyürek N, Hasanreisoğlu B (2010) Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits. Can J Microbiol 56:1–7
83. Yalçin B, Kalkanci A, Gürelik F, Fidan I, Kustimur S, Ozdek S (2010) In vitro synergistic effect of moxifloxacin and amphotericin B combination against Candida strains. Mikrobiyol Bul 44:65–70
84. Nakajima R, Kitamura A, Someya K, Tanaka M, Sato K (1995) In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother 39:1517–1521
85. Brilhante RSN, Caetano EP, Sidrim JJ, Cordeiro RA, Camargo ZP, Fechine MAB, Lima RAC, Castelo Branco DSCM, Marques FJF, Mesquita JRL, Lima DT, Monteiro AJ, Rocha MFG (2013) Ciprofloxacin shows synergism with classical antifungals against Histoplasma capsulatum var. capsulatum and Coccidioides posadasii. Mycoses 56:397–401
86. Vitale RG, Afeltra J, de Hoog GS, Rijs AJ, Verweij PE (2003) In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera. J Antimicrob Chemother 51:1297–1300
87. Matoba AY (2012) Fungal keratitis responsive to moxifloxacin monotherapy. Cornea 31:1206–1209
88. Shen LL, Baranowski J, Fostel J, Montgomery DA, Lartey PA (1992) DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob Agents Chemother 36:2778–2784
89. Elsea SH, Osheroff N, Nitiss JL (1992) Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J Biol Chem 267:13150–13153
90. Hsiung Y, Elsea SH, Osheroff N, Nitiss JL (1995) A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. J Biol Chem 270:20359–20364
91. Strumberg D, Nitiss JL, Rose A, Nicklaus MC, Pommier Y (1999) Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme–DNA and drug interactions. J Biol Chem 274:7292–7301
92. Dong J, Walker J, Nitiss JL (2000) A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons. J Biol Chem 275:7980–7987
93. Sarma PS (1989) Norfloxacin: a new drug in the treatment of falciparum malaria. Ann Intern Med 111:336–337
94. Tripathi KD, Sharma AK, Valecha N, Kulpati DD (1993) Curative efficacy of norfloxacin in falciparum malaria. Indian J Med Res 97:176–178
95. McClean KL, Hitchman D, Shafran SD (1992) Norfloxacin is inferior to chloroquine for falciparum malaria in northwestern Zambia: a comparative clinical trial. J Infect Dis 165:904–907
96. Hamzah J, Skinner-Adams T, Davis TME (2000) In vitro antimalarial activity of trovafloxacin, a fourth-generation fluoroquinolone. Acta Trop 74:39–42
97. Yeo AET, Rieckmann KH (1994) Prolonged exposure of Plasmodium falciparum to ciprofloxacin increases anti-malarial activity. J Parasitol 80:158–160
98. Bryskier A, Labro MT (1990) Quinolones and malaria: an avenue for the future. Quinolones Bull 6:1–4
99. Divo AA, Sartorelli AC, Patton CL, Bia FJ (1988) Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 32:1182–1186
100. Mahmoudi N, Ciceron L, Franetich JF, Farhati K, Silvie O, Eling W, Sauerwein R, Danis M, Mazier D, Derouin F (2003) In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodium spp. Antimicrob Agents Chemother 47:2636–2639
101. Watt G, Shanks GD, Edstein MD, Pavanand K, Webster HK, Wechgritaya S (1991) Ciprofloxacin treatment of drug-resistant falciparum malaria. J Infect Dis 164:602–604
102. Salmon D, Deloron P, Gaudin C, Malhotra K, Lebras J, Pocidalo JJ (1990) Activities of pefloxacin and ciprofloxacin against experimental malaria in mice. Antimicrob Agents Chemother 34:2327–2330
103. Keiser J, Burri C (2001) Evaluation of quinolone derivatives for antitrypanosomal activity. Trop Med Int Health 6:369–389
104. Nenortas E, Burri C, Shapiro TA (1999) Antitrypanosomal activity of fluoroquinolones. Antimicrob Agents Chemother 43:2066–2068
105. Nenortas E, Kulikowicz T, Burri C, Shapiro TA (2003) Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions. Antimicrob Agents Chemother 47:3015–3017
106. Gonzales-Perdomo M, de Castro SL, Meirelles MN, Goldenberg S (1990) Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors. Antimicrob Agents Chemother 34:1707–1714
107. Croft SL, Hogg J (1988) Limited activity of bacterial DNA topoisomerase II inhibitors against Leishmania donovani and Trypanosoma cruzi amastigotes in vitro. Trans R Soc Trop Med Hyg 82:856
108. Raether W, Seidenath H, Hofmann J (1989) Potent antibacterial fluoroquinolones with marked activity against Leishmania donovani in vivo. Parasitol Res 75:412–413
109. Sanguigni S, Marangi M, Gramiccia M, Orsini S, Paparo BS, Nicodemo G, Gradoni L (1993) Ciprofloxacin in the treatment of leishmaniasis. G Mal Infett Parassit 45:447–449
110. Savoia D, Biglino S, Cestaro A, Zucca M (1993) In vitro and in vivo activity of some fluoroquinolones on two Leishmania species. Eur Bull Drug Res 2:135–138
111. Romero IC, Saravia NG, Walker J (2005) Selective action of fluoroquinolones against intracellular amastigotes of Leishmania (Viannia) panamensis in vitro. J Parasitol 91:1474–1479
112. Didier ES, Bowers L, Stovall ME, Kuebler D, Mittleider D, Brindley PJ, Didier PJ (2005) Antimicrosporidial activity of (fluoro)quinolones in vitro and in vivo. Folia Parasitol (Praha) 52:173–181
113. Aboulaila M, Munkhjargal T, Sivakumar T, Ueno A, Nakano Y, Yokoyama M, Yoshinari T, Nagano D, Katayama K, El-Bahy N, Yokoyama N, Igarashi I (2012) Apicoplast-targeting antibacterials inhibit the growth of Babesia parasites. Antimicrob Agents Chemother 56:3196–3206
114. Khan AA, Slifer T, Araujo FG, Remington JS (1996) Trovafloxacin is active against Toxoplasma gondii. Antimicrob Agents Chemother 40:1855–1859
115. Khan AA, Araujo FG, Brighty KE, Gootz TD, Remington JS (1999) Anti-Toxoplasma gondii activities and structure–activity relationships of novel fluoroquinolones related to trovafloxacin. Antimicrob Agents Chemother 43:1783–1787
116. Gozalbes R, Brun-Pascaud M, Garcia-Domenech R, Galvez J, Girard PM, Doucet JP, Derouin F (2000) Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques. Antimicrob Agents Chemother 44:2771–2776
117. Chavalitshewinkoon-Petmitr P, Worasing R, Wilairat P (2001) Partial purification of mitochondrial DNA topoisomerase II from Plasmodium falciparum and its sensitivity to inhibitors. Southeast Asian J Trop Med Public Health 32:733–738
118. Weissig V, Vetro-Widenhouse TS, Rowe TC (1997) Topoisomerase II inhibitors induce cleavage of nuclear and 35-kb plastid DNAs in the malarial parasite Plasmodium falciparum. DNA Cell Biol 16:1483–1492
119. Prusty D, Dar A, Priya R, Sharma A, Dana S, Choudhury NR, Rao NS, Dhar SK (2010) Single-stranded DNA binding protein from human malarial parasite Plasmodium falciparum is encoded in the nucleus and targeted to the apicoplast. Nucleic Acids Res 38:7037–7053
120. Fichera ME, Roos DS (1997) A plastid organelle as a drug target in apicomplexan parasites. Nature 390:407–409
121. Goodman CD, Su V, McFadden GI (2007) The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol Biochem Parasitol 152:181–191
122. Dalhoff A (2005) Immunomodulatory activities of fluoroquinolones. Infection 33(Suppl 2):55–70
123. Dalhoff A, Shalit I (2003) Immunomodulatory effects of quinolones. Lancet Infect Dis 3:359–371
124. Dalhoff A, Döring G (1987) Action of quinolones on gene expression and bacterial membranes. In: Döring G, Holder IA, Botzenhart K (eds) Antibiotics and chemotherapy. Basic research and clinical aspects of Pseudomonas aeruginosa. Karger, Basel, Switzerland, pp 205–214